Class II Special Controls Guidance Document: Human Dura Mater; Guidance for Industry and FDA
Document Issued on: December 18, 2003
The draft of this document was issued on October 22, 2002.
This document supersedes Guide for the Preparation of a Premarket Notification Application for Processed Human Dura Mater, issued October 14, 1999.
For questions regarding this document, contact Richard McFarland at 301-827-5352 or by email at firstname.lastname@example.org.
U.S. Department of Health and Human Services
Plastic and Reconstructive Surgery Devices Branch
Comments and suggestions may be submitted at any time for Agency consideration to Divison of Dockets Management Branch, Food and Drug Administration, 5630 Fishers Lane, Room 1061, (HFA-305), Rockville, MD, 20852. Alternatively, electronic comments may be submitted to Regulations.gov. When submitting comments, please refer to Docket No. 02D-0371. Comments may not be acted upon by the Agency until the document is next revised or updated.
Additional copies are available from the Internet, or to receive this document by fax, call the CDRH Facts-On-Demand system at 800-899-0381 or 301-827-0111 from a touch-tone telephone. Press 1 to enter the system. At the second voice prompt, press 1 to order a document. Enter the document number (054) followed by the pound sign (#). Follow the remaining voice prompts to complete your request.
TABLE OF CONTENTS
3. THE CONTENT AND FORMAT OF AN ABBREVIATED 510(K) SUBMISSION
4. HUMAN DURA MATER
6. RISKS TO HEALTH
7. DONOR QUALIFICATION
8. QUALIFICATION OF OTHER COMPONENTS
9. DEVICE PROCESSING METHODS
10. DEVICE MANUFACTURING: MANUFACTURING CONTROLS
11. FINAL STERILIZATION
Guidance for Industry and FDA Staff
Class II Special Controls Guidance Document: Human Dura Mater
This guidance document was developed as a special controls guidance to support the classification of the human dura mater device into class II. The device is intended to repair defects in the dura mater. This guidance document is issued in conjunction with a Federal Register notice announcing the classification of the human dura mater device.
Following the effective date of the final classification rule, any firm submitting a premarket notification (510(k)) for a human dura mater device will need to address the issues covered in the special controls guidance document. The firm must show that its device addresses the issues of safety and effectiveness identified in this guidance, either by meeting the recommendations of this guidance or by some other means that provides equivalent assurances of safety and effectiveness.
FDA believes that special controls, when combined with the general controls, will be sufficient to provide reasonable assurance of the safety and effectiveness of the human dura mater device. Thus, a manufacturer who intends to market a device of this generic type should (1) conform to the general controls of the Federal Food, Drug & Cosmetic Act (the Act), including the 510(k) requirements described in 21 CFR 807 Subpart E, (2) address the specific risks to health associated with the human dura mater device identified in this guidance, and (3) obtain a substantial equivalence determination from FDA prior to marketing the device, unless exempt from the premarket notification requirements of the Act (refer to 21 CFR 807.85).
This special controls guidance document identifies the classification regulation and product code for the human dura mater device (Refer to Section 5 – Scope). In addition, other sections of this special controls guidance document list the risks to health identified by FDA and describe measures that, if followed by manufacturers and combined with the general controls, will generally address the risks associated with these human dura mater devices and lead to a timely 510(k) review and clearance. This document supplements other agency documents regarding the specific content requirements of a 510(k) submission. You should also refer to 21 CFR 807.87 and other agency information on this topic, such as CDRH’s Device Advice on the Internet.
As described in the guidance entitled, The New 510(k) Paradigm - Alternate Approaches to Demonstrating Substantial Equivalence in Premarket Notifications; Final Guidance, a manufacturer may submit a Traditional 510(k) or has the option of submitting either an Abbreviated 510(k) or a Special 510(k). FDA believes an Abbreviated 510(k) provides the least burdensome means of demonstrating substantial equivalence for a new device, particularly once a special controls guidance document has been issued. Manufacturers considering modifications to their own cleared devices may lessen the regulatory burden by submitting a Special 510(k).
The Least Burdensome Approach
The issues identified in this guidance document represent those that we believe need to be addressed before your device can be marketed. In developing the guidance, we carefully considered the relevant statutory criteria for Agency decision-making. We also considered the burden that may be incurred in your attempt to comply with the statutory and regulatory criteria in the manner suggested by the guidance and in your attempt to address the issues we have identified. We believe that we have considered the least burdensome approach to resolving the issues presented in the guidance document. If, however, you believe that there is a less burdensome way to address the issues, you should follow the procedures outlined in the “A Suggested Approach to Resolving Least Burdensome Issues” document.
An Abbreviated 510(k) submission must include the required elements identified in 21 CFR 807.87, including the proposed labeling for the device sufficient to describe the device, its intended use, and the directions for its use. In an Abbreviated 510(k), FDA may consider the contents of a summary report to be appropriate supporting data within the meaning of 21 CFR 807.87(f) or (g); therefore, we recommend that you include a summary report. The report should describe how this special controls guidance document was used during the device development and testing and should briefly describe the methods or tests used and a summary of the test data or description of the acceptance criteria applied to address the risks identified in this guidance document, as well as any additional risks specific to your device. This section suggests information to fulfill some of the requirements of 21 CFR 807.87, as well as some other items that we recommend you should include in an Abbreviated 510(k).
The coversheet should prominently identify the submission as an Abbreviated 510(k) and cite the title of this Class II Special Controls Guidance Document.
Proposed labeling should be sufficient to describe the device, its intended use, and the directions for its use. (Refer to Section 12 for specific information that we recommend including in the labeling for devices of the type covered by this guidance document.)
We recommend that the summary report contain a:
- Description of the device and its intended use. We recommend that the description include a complete discussion of the performance specifications and, when appropriate, detailed, labeled drawings of the device. You should also submit an "indications for use" enclosure.1
- Description of device design requirements.
- Identification of the Risk Analysis method(s) used to assess the risk profile in general as well as the specific device’s design and the results of this analysis. (Refer to Section 6 for the risks to health generally associated with the use of this device that FDA has identified.)
- Discussion of the device characteristics that address the risks identified in this Class II Special Controls Guidance Document, as well as any additional risks identified in your risk analysis.
- Brief description of the test method(s) you have used or intend to use to address each performance aspect identified in Sections 7-11 of this Class II Special Controls Guidance Document. If you follow a suggested test method, you may cite the method rather than describing it. If you modify a suggested test method, you may cite the method but should provide sufficient information to explain the nature of and reason for the modification. For each test, you may either (1) briefly present the data resulting from the test in clear and concise form, such as a table, or (2) describe the acceptance criteria that you will apply to your test results.2 (See also 21 CFR 820.30, Subpart C - Design Controls for the Quality System Regulation.)
- If any part of the device design or testing relies on a recognized standard, (1) a statement that testing will be conducted and meet specified acceptance criteria before the product is marketed, or (2) a declaration of conformity to the standard.3 Please note that testing must be completed before submitting a declaration of conformity to a recognized standard. (Section 514(c)(1)(B) of the Act). For more information, see FDA guidance, Use of Standards in Substantial Equivalence Determinations; Final Guidance for Industry and FDA.
If it is not clear how you have addressed the risks identified by FDA or through your risk analysis, we may request additional information about aspects of the device’s performance characteristics. We may also request additional information if we need it to assess the adequacy of your acceptance criteria. (Under 21 CFR 807.87(l), we may request any additional information that is necessary to reach a determination regarding substantial equivalence.)
As an alternative to submitting an Abbreviated 510(k), you can submit a traditional 510(k) that provides all of the information and data required under 21 CFR 807.87 and described in this guidance. A traditional 510(k) should include all of your methods, data, acceptance criteria, and conclusions. Manufacturers considering modifications to their own legally marketed devices should consider submitting Special 510(k)s.
The general discussion above applies to any device subject to a special controls guidance document. The following is a specific discussion of how we recommend that you apply this Class II Special Controls Guidance Document to a premarket notification for a human dura mater device.
A. Human Dura Mater and Creutzfeldt Jakob Disease
- In February 1987, the Center for Disease Control and Prevention (CDC) reported the first U.S. case of Creutzfeldt Jakob Disease (CJD) in an individual who had received a human dura mater graft. CJD is a rare, invariably fatal degenerative disease of the central nervous system characterized by progressive dementia. In 1996, a nationwide CJD survey in Japan identified 43 cases associated with implantation of processed human dura mater. This increased the worldwide total of published cases of CJD associated with human dura mater use to 62. The great majority of these cases (59 out of 62) were related to the use of Lyodura, a particular brand of human dura mater manufactured in Germany. It should be noted that Lyodura was never cleared for commercial distribution in the U.S. and the import alert issued by FDA in June 1987 for this product continues to be in effect as of the issuance of this guidance.
- In March 1997, the World Health Organization (WHO) recommended that human dura mater grafts no longer be used, especially in neurosurgery, unless no alternative was available. At the same time, the Japanese Health and Welfare Ministry banned the use of human dura mater in brain surgery in Japan.
- FDA established safeguards and guidelines in 1990 in an effort to minimize the possibility of CJD transmission by human dura mater device implantation. As of March 1997, there were no confirmed cases of CJD-transmission related to the use of human dura mater that was legally cleared for U.S. commercial distribution. Therefore, in 1997, FDA decided not to restrict the distribution of human dura mater in the United States. FDA also decided to hold public meetings of the FDA Transmissible Spongiform Encephalopathies Advisory Committee (TSEAC) to re-evaluate the safety of human dura mater grafts with respect to surgical use and CJD transmission.
- On October 6, 1997, the TSEAC met to consider information provided by the FDA, industry, the Centers for Disease Control, the National Institutes of Health, the neurology medical community, and other internationally recognized experts and make recommendations concerning the clinical benefits and risks of CJD transmission associated with human dura mater grafts. At the conclusion of this meeting, the TSEAC recommended unanimously that neurosurgeons should avoid the use of human dura mater whenever possible. The committee also concluded, however, that the final decision regarding use of human dura mater should be left to the discretion of the treating neurosurgeon, as long as the human dura mater is procured and processed following certain safety measures.
- Based upon the TSEAC’s recommendations, on March 6, 1998, FDA sent letters to suppliers of human dura mater requesting that they implement specific measures to improve the safety of human dura mater.
- At the April 16, 1998, TSEAC meeting, FDA presented proposed revisions to the TSEAC’s recommendations offered during their October 6, 1997, meeting. These revisions took into consideration the responses from the human dura mater suppliers to the FDA letter of March 6, 1998. Those sponsor’s responses raised concerns about the feasibility or necessity of some of the recommendations. Transcripts for TSEAC meetings are available on the Internet.
- On January 18-19, 2001, the TSEAC also discussed criteria for determining the suitability of donors of human cells, tissues, and cellular and tissue-based products with regard to CJD and variant CJD (vCJD). The recommendations provided by the TSEAC at this meeting are also incorporated into this revised guidance document.
- FDA considered the concerns raised in an August 15, 2001, citizen’s petition (01P-O354) submitted by Public Citizen. The petition requested that FDA ban and recall all human dura mater devices. (On February 11, 2002, FDA responded to the petitioner finding that the currently available information did not satisfy the statutory requirements for banning and/or recalling human cadaveric dura mater.)
- While reagents for proteinase-resistant prion protein (PrP-RES) testing of brain tissue are available from certain research laboratories, testing is currently a research/investigational-use tool (Ref. 1). There is currently no FDA-approved or validated PrP-RES test that is marketed for screening donors for CJD. However, when either a validated test becomes available or evaluation of available data demonstrates the utility of PrP-RES testing as an aid in determining that brain and dura mater tissues are not contaminated with CJD, incorporating PrP-RES testing into standard operating procedures will be recommended.
B. Regulatory History
- Although not the primary purpose of this guidance document, FDA would also like to clarify the regulatory history of human dura mater. Human dura mater was in commercial distribution before the enactment of the Medical Device Amendments of 1976 to the Federal Food, Drug, and Cosmetic Act. The Neurological Devices Advisory Panel (the Panel) initially made a classification recommendation at the February 2, 1990 meeting. Because product classification was not finalized and new information about the safety of this device became available during the following nine years, FDA requested a second classification recommendation from the Panel on September 16, 1999. Regulation as a class II device was recommended at both Panel meetings.
- In February 1997, FDA proposed a risk-based approach to the regulation of human cellular and tissue-based products (Ref. 2). To implement the proposed approach, FDA has published three proposed rules. “Human Cells, Tissues, and Cellular and Tissue-Based Products; Establishment Registration and Listing; Final Rule” has been finalized (Ref. 3). The comment periods for the two other proposed rules “Suitability of Donors of Human Cellular and Tissue-Based Products; Proposed Rule” (Ref. 4), and “Current Good Tissue Practice for Manufacturers of Human Cellular and Tissue-Based Products; Proposed Rule” (Ref. 5), have closed and comments are being reviewed.
- FDA intends to redesignate the regulation of human dura mater from the medical device authorities to the human tissue regulations under the legal authority of Section 361 of the Public Health Service Act. However, the precise date of this transfer is dependent upon implementation of the above cited rules.
- Until regulatory authority for dura mater is transferred, human dura mater will continue to be regulated as a device. Therefore, FDA is providing the information below to help 510(k) submitters submit sufficient information to demonstrate reasonable assurance of the safety and effectiveness for these devices as described in 21 CFR 860.7(g)(2) (Ref. 6).
The scope of this document is limited to the human dura mater device, regulation number 21 CFR 882.5975, and product code LEM. A human dura mater device is human pachymeninx tissue intended to repair defects in the dura mater.
§ 882.5975 Human dura mater.
a. Identification. Human dura mater is human pachymeninx tissue intended to repair defects in human dura mater.
b. Classification. Class II (special controls). The special control for this device is FDA’s “Class II Special Controls Guidance Document: Human Dura Mater.”
Human dura mater devices should not be confused with dura mater substitute devices, which are classified under 21 CFR 882.5910, product code GXQ.
In the table below, FDA has identified the risks to health generally associated with the use of the human dura mater device addressed in this document. The measures recommended to mitigate these identified risks are given in this guidance document, as shown in the table below. You should also conduct a risk analysis, prior to submitting your 510(k), to identify any other risks specific to your device. The 510(k) should describe the risk analysis method. If you elect to use an alternative approach to address a particular risk identified in this guidance document, or have identified risks additional to those in the guidance, you should provide sufficient detail to support the approach you have used to address that risk.
|Identified risk||Recommended mitigation measures|
|Infection related to patient condition and treatment||Sections 7-11|
|Transmission of spongiform encephalopathies||Sections 7-10, 12|
|CSF leakage||Sections 9-10|
|Adverse tissue reactions||Sections 9-11|
A. Serology Testing
A blood specimen from all potential donors should be tested and found negative for pathogens of concern using legally marketed screening tests. Currently, that list includes the human immunodeficiency virus, Type 1 and Type 2 (anti-HIV-1 and anti-HIV-2), hepatitis B surface antigen (HBsAg), and antibodies to the hepatitis C virus (anti-HCV). Tests must be performed in a CLIA-certified laboratory, 42 CFR Part 493. Screening tests that have been licensed for testing cadaveric blood should be used, when available.
B. Evaluating risk factors for, and clinical evidence of, neurological and infectious diseases through medical record review and donor history interviews
We recommend that each 510(k) describe the methods for evaluating the possible presence of risk factors for, and clinical or physical evidence of, neurologic or infectious disease. For example:
All available information, including a donor's medical records, autopsy reports, or any physical assessment reports (e.g., medical examiner report, police records) should be reviewed to determine donor suitability. These records should be evaluated by an individual who is qualified by profession, education, and training and who is familiar with the intended use of human dura mater.
Interviews should also be performed with one or more individuals who can provide reliable information (e.g., a donor's next of kin, a relative, a member of the donor's household, an individual with an affinity relationship with the donor, or the donor's primary treating physician) concerning the donor's medical history and relevant social behavior. The interview should determine whether the donor had signs or symptoms of neurologic disease or engaged in certain activities or behaviors that place a donor at a high risk for HIV or hepatitis infection.
The interview should also seek to determine whether the potential dura mater donor traveled or resided in a BSE-identified country during the time and for a duration that would defer an individual as a blood donor. CBER’s blood donor selection criteria regarding CJD are described in the “Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products” (Ref. 7). FDA believes that applying the blood donor selection criteria when considering potential human dura mater donors is appropriate given the current lack of information available about the incidence and transmissibility of vCJD.
The manufacturer should establish donor selection criteria and develop standardized methods for reviewing medical records and performing interviews. Such procedures should draw upon the appropriate standards of voluntary organizations (e.g., American Association of Tissue Banks and Eye Bank Association of America) as well as the recommendations, guidelines, and regulations of Public Health Service agencies (Refs. 8-17).
We recommend that exclusion criteria include, but not be limited to, the following:
Regarding neurological screening
- donors diagnosed with CJD or a known family history (blood relative) of a person with non-iatrogenic CJD
- donors who received injections of human pituitary-derived growth hormone (pit-hGH)
- donors who received transplants of dura mater
- donors diagnosed with any degenerative or demyelinating disease of the CNS (e.g., multiple sclerosis) or other neurologic diseases (e.g., senile dementia, Alzheimer’s disease)
- donors who died in a neurological/psychiatric hospital.
Other exclusion criteria
- donors who meet the exclusion criteria for potential infectious disease described in the “Guidance for Industry: Screening and Testing of Donors of Human Tissue Intended for Transplantation” (Ref. 15)
- donors diagnosed with active infections at the time of death (e.g., rheumatic fever, generalized septicemia or systemic infection, mycosis, tuberculosis)
- donors diagnosed with diseases of unknown etiology
- donors without adequate documentation of medical history.
C. Physical Assessment
The 510(k) should identify standardized donor selection criteria for physically assessing a cadaver in a general autopsy. Exclusion criteria based on clinical evidence of possible infectious or neurologic diseases should include, but not be limited to, evidence of:
- physical evidence for risk of sexually transmitted diseases, such as genital ulcerative disease, herpes simplex, and syphilis
- physical evidence of anal intercourse, including perianal condyloma
- physical evidence of non-medical percutaneous drug use, such as needle tracks
- disseminated lymphadenopathy
- oral thrush
- blue or purple spots consistent with Kaposi's sarcoma
- needle tracks, including examination of tattoos which may be covering needle tracks
- unexplained jaundice, hepatomegaly, or icterus
- if the body was rejected for routine autopsy due to infectious criteria or if the autopsy was done in an infectious disease control room or under any special precautions and the reasons for these procedures.
D. Gross and Histological Examination of the Brain
The 510(k) should describe the procedures for performing a full autopsy on each donor's brain. Following fresh examination, the brain should be fixed, sliced, gross examination of the entire brain conducted, including multiple cross sections, and multiple samples of tissue obtained from different parts of the brain for histologic examination. This examination should be performed by a qualified pathologist after human dura mater collection. Potential donors should be excluded when any possible evidence of TSE-related changes is observed during gross and histological examination of the brain (Refs. 1, 18-20).
E. Archiving of Donor Brain and Dura Mater Tissue
FDA recommends that frozen (at a temperature equal to or less than -70?C) and fixed samples of both donor brain and dura mater tissues should be archived. The donor brain samples should include at least 5 grams of the frontotemporal region.
These samples should be retained for 10 years based on the current scientific knowledge regarding the development of screening tests and our expectation that, as the science evolves, screening tests may become available within that time.
While archiving samples of donor brain and dura mater may not immediately increase the assurance of dura mater graft safety, comprehensive collection and storage of such tissues would permit subsequent testing for TSE-induced changes when improved or new test methods become available. In the event that a human dura mater-graft recipient becomes ill with CJD, testing of archival donor material might assist in determining whether the dura mater graft was the source of infection.
The source and purity of all other components and manufacturing materials (e.g., preservatives) should be identified in the 510(k). Such information may be supplied by reference to a Master File(s) if a letter of cross-reference is included that authorizes FDA review of the appropriate documents. Submission of a Certificate(s) of Analysis (CoA) and/or a Materials Safety Data Sheet(s) (MSDS) for each device component can also greatly simplify the 510(k) review.
A. Manufacturing Reagents
The 510(k) should contain information about all reagents (e.g., organic solvents) and processing methods used in device manufacture. Information similar to that discussed above for device components, (i.e., reagent source, purity, CoA and/or MSDS) can be very helpful in evaluating the substantial equivalence of the proposed and legally marketed devices. The 510(k) should also identify the concentration in the final device of any manufacturing reagent that is potentially toxic.
B. CJD Disinfection
Careful control of donor selection and dura mater retrieval procedures constitute critical safety practices for human dura mater. While histological examination of the brain may detect most infected tissues, it may not identify all CJD-infected grafts. Therefore, treatment of each product with a generally accepted disinfection technique should be performed to provide an additional assurance of device safety. The TSEAC recommended treating human dura mater with 1.0 N sodium hydroxide (NaOH). This recommendation was based on a study in an animal model in which 1.0 N NaOH treatment reduced CJD infectivity (Ref. 18). Each 510(k) should provide information about the methods for disinfection with NaOH or another procedure that has been validated to significantly reduce CJD infectivity. Such data should also demonstrate that subsequent rinsing steps are sufficient to reduce the concentration of residual NaOH (or another disinfectant) to a non-cytotoxic level and that the human dura mater retains its clinical utility.
Because product specifications and end-product testing alone are insufficient to control critical characteristics of this product, the manufacturer should carefully monitor donor selection, tissue collection procedures, device processing, packaging, and distribution to achieve a reasonable assurance of product safety.
A. Excision Procedures
Written procedures should require aseptic conditions for handling of all tissues. Tissue recovery should be performed within 24 hours of death and with sufficient temperature control to limit the effects of autolysis.
B. Excision Facilities
The excision facility (morgue) should meet the minimum standards of a surgical operating room. The excisional facility should have:
• air filtration
• stainless steel furniture
• washable walls
• refrigeration for cadaver storage
• hypothermia blankets to cool the cadaver during the procedure
• single use or disposable instruments and processing aids for each donor.
C. Batch Processing
Human dura mater grafts from different donors should not be co-mingled during tissue collection or product manufacture. The 510(k) should describe efforts to eliminate opportunities for cross-contamination during tissue collection and processing as well as the procedures employed to prohibit batch processing of material from different donors. For example, procedures should require the use of only disposable processing materials and surgical instruments during the recovery and processing of dura mater allografts. Because FDA is unaware of any procedure or reagent that is validated to totally inactivate the CJD-causing agent, FDA would welcome any information that supports an alternative approach to the sole use of disposable processing materials and surgical instruments.
D. Record Keeping/Tissue Tracking
As described in 21 CFR 820.60 subpart F, each manufacturer must establish and maintain procedures for identifying the product during all stages of receipt, production, distribution, and application. The 510(k) should describe the methods for tracking each lot of final product directly back to the tissue donor as it relates to donor medical records and device manufacturing records.
Although not required to be submitted as part of the 510(k), the manufacturer should maintain the following data as part of the donor medical records:
- the record of the time of death and certification of the time of tissue recovery
- the results of post-mortem examination and serological studies sufficient to evaluate the potential of communicating infectious, malignant, and/or neurological disease or to detect diseases of unknown etiology
- the record of compliance with the written procedures for recovery.
For additional information regarding device manufacturing records, the manufacturer should refer to 21 CFR 820 subpart M (Quality System Regulations).
For additional information regarding the tracking regulation, please refer to 21 CFR Part 821, Section 519(e) of the Act, and the guidance entitled Medical Device Tracking; Guidance for Industry and FDA Staff for additional information on procedures for tracking medical devices.
For devices labeled as sterile, a sterility assurance level (SAL) of 10 6 is recommended. All sterility data should be obtained by methods consistent with a recognized standard or guidance for assessing the ability of the manufacturing and sterilization processes to inactivate bacteria, fungi and yeast (e.g., Updated 510(k) Sterility Review Guidance K90-1; Final Guidance for Industry and FDA. In addition, the manufacturing methods should demonstrate that the sum of the log clearance of virus from manufacturing and sterilization processes are at least six logs greater than the concentration of virus anticipated in the unprocessed source material. Studies determining the viral inactivation properties may be performed with selected scaled down versions of the specific manufacturing and sterilization processes using appropriate model viruses. FDA recommends review of the “Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin” (Ref. 21) for information about the design of such studies and the selection of model viruses.
Regarding final sterilization procedures, the 510(k) should describe:
- the method of sterilization
- the validation method for the sterilization cycle
- the SAL to be achieved
- the method for monitoring the sterility of each production lot.
If radiation sterilization is used, the sterilizing dose and methods for monitoring exposure level should be specified. If ethylene oxide (EtO) sterilization is performed, the application should describe the methods by which residual levels of ethylene oxide, ethylene chlorohydrin, and ethylene glycol are determined and the amount of EtO and residues remaining on/in the device. Because EtO and its decomposition products may be very neurotoxic, specifications for EtO residuals should be set at a non-cytotoxic level. Review of “Guidance for ANSI/AAMI/ISO 10993-7: 1995, Biological evaluation of medical devices-Part 7: Ethylene oxide sterilization residuals” is recommended.
The premarket notification should include labeling in sufficient detail to satisfy the requirements of 21 CFR 807.87(e). The following suggestions are aimed at assisting you in preparing labeling that satisfies the requirements of 21 CFR 807.87(e).4
In accordance with 21 CFR 801.109, this device must bear the following caution statement: “Caution: Federal law restricts this device to sale by or on the order of a physician.”
The labeling should include information so that the graft recipient is notified in writing that she/he has received a human dura mater graft implant.
The labeling should permit information on tissue sourcing to be maintained in the recipient’s hospital record.
Because the WHO and the TSEAC have stated potential concerns related to potential CJD and vCJD transmission, product labeling should remind practitioners to consider the risks and benefits of human dura mater implantation, including the use of alternative products and procedures.
1. Kretzschmar, H.A., Ironside, J.W., DeArmond, S.J., and Tateishi, J., “Diagnostic Criteria for Sporadic Creutzfeldt-Jakob Disease,” Arch. Neurol. 1996; 53:913-920.
3. “Establishment Registration and Listing for Manufacturers of Human Cellular and Tissue-Based Products” (66 FR 5447, January 19, 2001).
4. “Suitability Determination for Donors of Human Cellular and Tissue-Based Products” (64 FR 52696, September 30, 1999).
5. “Current Good Tissue Practice for Manufacturers of Human Cellular and Tissue-Based Products; Inspection and Enforcement” (66 FR 1507, January 8, 2001).
6. “The Commissioner may require that a manufacturer, importer, or distributor make reports or provide other information bearing on the classification of a device and indicating whether there is reasonable assurance of the safety and effectiveness of the device or whether it is adulterated or misbranded under the act.” (21 CFR 860.7(g)(2))
7. “Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products,” 8/27/01, available at http://www.fda.gov/cber/gdlns/cjdvcjd.htm.
8. FDA Recommendations to Blood Establishments for “The Management of Donors and Units that are Initially Reactive for Hepatitis B Surface Antigen (HBsAg),” 12/2/87.
9. FDA Recommendations to Blood Establishments for “Donor Suitability Related to Laboratory Testing for Viral Hepatitis and a History of Viral Hepatitis,” 12/22/93.
10. PHS Guideline for Preventing Transmission of HIV through Transplantation of Human Tissue and Organs, MMWR: 43: 1-17, 1994.
11. PHS Guideline for Screening Donors of Blood, Plasma, Organs, Tissue and Semen for Evidence of Hepatitis B and Hepatitis C, MMWR: 40:1-17, 1991.
12. FDA Recommendations to Blood Establishments for “Deferral of Current and Recent Inmates of Correctional Institutions as Donors of Whole Blood, Blood Components, Source Leukocytes, and Source Plasma,” 6/8/95.
13. FDA Recommendations to Blood Establishments for “Precautionary Measures to Further Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease by Blood and Blood Products,” 8/8/95.
14. FDA Recommendations to Blood Establishments for “Deferral of Blood and Plasma Donors based on Medications,” 7/28/93.
15. FDA Guidance for Industry: Screening and Testing of Donors of Human Tissue Intended for Transplantation, July 1997.
16. FDA Revised Recommendations to Blood Establishments for “Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV),” 4/23/92.
17. FDA Revised Recommendations to Blood Establishments for “The Prevention of Human Immunodeficiency Virus (HIV) Transmission by Blood and Blood Products,” 4/23/92.
18. Diringer, H. and Braig, H.R., “Infectivity of Unconventional Viruses in Dura Mater,” Lancet 1989 Feb 25;1(8635):439-40
19. Johnson, R.T. and Gibbs, C.L., “Creutzfeldt-Jakob Disease and Related Transmissible Spongiform Encephalopathies,” NEJM, 339, 1994-2004 (1998).
20. Lantos, P.L., Bhatia, K., Doey, L.J., al-Sarraj, S., Doshi, R., Beck, J. and Collinge, J. “Is the neuropathology of new variant Creutzfeldt-Jakob disease and kuru similar?” Lancet 1997 Jul 19;350 (9072):187-8
21. Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin” <1050> USP 24
1Refer to Indications for Use Form (PDF File Size: 1.03MB) for the recommended format.
2If FDA makes a substantial equivalence determination based on acceptance criteria, the subject device should be tested and shown to meet these acceptance criteria before being introduced into interstate commerce. If the finished device does not meet the acceptance criteria, and thus differs from the device described in the cleared 510(k), FDA recommends that submitters apply the same criteria used to assess modifications to legally marketed devices (21 CFR 807.81(a)(3)) to determine whether marketing of the finished device requires clearance of a new 510(k).
3See Required Elements for a Declaration of Conformity to a Recognized Standard (Screening Checklist for All Premarket Notification [510(K)] Submissions).
4Although final labeling is not required for 510(k) clearance, final labeling must also comply with the requirements of 21 CFR 801 before a medical device is introduced into interstate commerce. In addition, final labeling for prescription medical devices must comply with 21 CFR 801.109. Labeling recommendations in this guidance are consistent with the requirements of part 801.